Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | PRKCG | P05129 | 1/20 | 0.31 |
| ▸ | PRKCB | P05771 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PRKCH | P24723 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.31 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29307606 | 0.83 | PPARG (0.38) | AHCYALDH1A1LGALS3 | |
| SCHEMBL27737655 | 0.83 | LGALS3 (0.43) | AHCYTSHRALDH1A1PRKD3PRKCG | |
| SCHEMBL2189191 | 0.80 | TSHR (0.45) | TSHRALDH1A1AKT1 | |
| SCHEMBL2189182 | 0.80 | TSHR (0.45) | TSHRALDH1A1AKT1 | |
| SCHEMBL27104270 | 0.80 | CAPN1 (0.34) | AHCY | |
| SCHEMBL25154995 | 0.79 | IDUA (0.35) | AHCY | |
| SCHEMBL20442291 | 0.79 | IDUA (0.35) | AHCY | |
| SCHEMBL28833013 | 0.79 | TSHR (0.44) | TSHRALDH1A1AKT1 | |
| SCHEMBL29981924 | 0.78 | TSHR (0.46) | TSHRALDH1A1 | |
| SCHEMBL28475631 | 0.78 | LGALS3 (0.33) | LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200113912-A1 | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates | SILVERBACK THERAPEUTICS, INC. (US) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113912-A1 | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates | CD74, CD47, CD69 | AHCY 1271/4885TSHR 1563/4885ALDH1A1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.